

**Shield Therapeutics plc  
("Shield Therapeutics" or the "Company")**

**Investor Presentation**

**London, UK - 3 March 2021:** Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company, announces that it will provide a live presentation on Tuesday 9 March 2021 at 4.00pm covering the recent £25m fundraise and Open Offer to raise up to £4.2m and the US market opportunity ahead.

CEO, Tim Watts will present and introduce Brian Groch, who will run the Company's US commercial operations. Brian has some 30 years' commercial experience gained from working with a range of pharmaceutical and biotechnology companies.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and request to meet Shield Therapeutics plc via the following link: <https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor>

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of regulations and information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

**For further information, please contact:**

**Shield Therapeutics plc**  
Tim Watts (CEO)

+44 (0) 191 511 8500

**Peel Hunt LLP - Nominated Adviser, Joint Broker  
and Bookrunner**

+44 (0) 20 7148  
8900

James Steel / Oliver Jackson (Investment  
Banking)  
Jock Maxwell Macdonald / Sohail Akbar  
(ECM)

**finnCap Ltd - Joint Broker and  
Bookrunner**

+44 (0) 20 7220 0500

Geoff Nash / Matthew Radley (Corporate  
Finance)  
Alice Lane / Charlotte Sutcliffe (ECM)

**Walbrook PR - Financial PR & IR Adviser**

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne

or [shield@walbrookpr.com](mailto:shield@walbrookpr.com)

**About Shield**

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see [www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUOSURAVUORAR